Provided by Tiger Trade Technology Pte. Ltd.

AKESO

108.700
+2.4002.26%
Volume:16.11M
Turnover:1.72B
Market Cap:100.11B
PE:-88.18
High:109.900
Open:102.100
Low:101.000
Close:106.300
52wk High:156.000
52wk Low:80.200
Shares:921.00M
HK Float Shares:921.00M
Volume Ratio:1.39
T/O Rate:1.75%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-1.233
ROE:-13.59%
ROA:-4.57%
PB:10.09
PE(LYR):-88.18
PS:24.81

Loading ...

Major Drugmakers Turn to China for Licensing Deals

Reuters
·
Yesterday

Daiwa: Akeso's Global Partner Summit Secures AstraZeneca Investment, Boosting Ivonescimab's Global Peak Sales Potential

Stock News
·
Yesterday

Nomura Assigns HK$138.29 Target Price and "Buy" Rating to Akeso

Stock News
·
Yesterday

Movement Alert|AKESO Falls 3.86% in Regular Trading, Profit-Taking After Previous Session Surge of Over 15% on AstraZeneca-Summit Deal

Market Focus
·
Yesterday

Hong Kong Stock Connect Innovative Drug Sector Defies Market Downturn as Top Pharmaceutical Firm Enters with US$2 Billion, Akeso Surges 15.54%, Hengrui Pharma Secures US$2.6 Billion BD Deal

Deep News
·
Sep 29

Akeso, Inc. (09926): Yu Xia Acquires Shares, Long Position Rises to 25.0%

HK Disclosure
·
Sep 29

China A-Share Indices Reverse Early Gains as Real Estate Stocks Surge, Vanke Hits Limit Up, Biotech Rallies, Hang Seng Tech Falls Over 1%, New Energy Vehicle Shares Decline

Deep News
·
Sep 29

Hong Kong Stocks Open: Hang Seng Index Turns Lower After Flat Start; Pharma Shares Defy Trend as AKESO Surges Nearly 10%

Stock News
·
Sep 29

AKESO Jumps as AstraZeneca's $2B Strategic Investment in Summit Provides Top-Tier Pharma Endorsement for Ivonescimab

Market Focus
·
Sep 29

Akeso Biotech Jumps Over 8% at Open as AstraZeneca Makes US$2 Billion Strategic Investment in Summit, Ivonescimab Gains Backing from Top Pharma

Stock News
·
Sep 29

AstraZeneca's $2 Billion Stake in Summit Signals Confidence in Akeso's Ivonescimab

Deep News
·
Sep 29

Akeso: Zhongmin Maxwell Wang Passively Diluted, Long Position Falls to 4.67%

HK Disclosure
·
Sep 28

Akeso Announces First Patient Enrolled in Global Phase Iii Trial of Cadonilimab Versus Nivolumab in First-Line Gastric Cancer

THOMSON REUTERS
·
Sep 28

Movement Alert|AKESO Declines 3.18% in Regular Trading, Profit-Taking Resumes After Volatile Swing on HARMONi-2 Data

Market Focus
·
Sep 24

Movement Alert|AKESO Rises 3.39% in Regular Trading, Rebounding After Prior Session Pullback as HARMONi-2 OS Data Continues to Drive Sentiment

Market Focus
·
Sep 23

Movement Alert|AKESO Declines 3.07% in Regular Trading, Pullback After Previous Session Surge of Nearly 9%

Market Focus
·
Sep 22

Akeso Says Phase III HARMONi-GI1 Overall Survival Data for Ivonescimab in First-Line Biliary Tract Cancer Wins ESMO Late-Breaking Slot

Reuters
·
Sep 22

Market Chatter: US Considers Rules Allowing American Investment in Chinese Drugs

MT Newswires Live
·
Sep 21

Innovative Drug Stocks Surge Across the Board in Morning Session, with Keymed Bio-B and Akeso Both Climbing Over 9%

Deep News
·
Sep 21

HK Movers | Innovative Drug Stocks Rally Broadly; LEPU BIO, INNOCARE, AKESO Jump Over 7%

Tiger Newspress
·
Sep 21